XON - Intrexon Corporation

NYSE - Nasdaq Real Time Price. Currency in USD
16.40
+0.25 (+1.55%)
As of 3:38PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close16.15
Open16.09
Bid16.32 x 800
Ask16.35 x 1000
Day's Range15.49 - 16.50
52 Week Range10.26 - 25.88
Volume837,294
Avg. Volume1,171,549
Market Cap2.12B
Beta1.45
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire8 hours ago

    Ziopharm Oncology Reports on Status of Investigational New Drug Application for Phase 1 Trial to Evaluate CD19-targeted CAR T Therapy

    Ziopharm, Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation (XON) and The University of Texas MD Anderson Cancer Center, the IND sponsor, are seeking to conduct a clinical trial to evaluate CAR+ T cells manufactured with Sleeping Beauty technology as an investigational treatment for patients with relapsed or refractory, CD19+ leukemias and lymphomas. CAR+ T cells very-rapidly manufactured with the Sleeping Beauty platform for this third-generation trial are designed to co-express CD19-specific chimeric antigen receptor, or CAR, membrane-bound interleukin 15 and a safety switch.

  • GlobeNewswire14 days ago

    Ziopharm Oncology Presents Clinical Data Demonstrating Anti-tumor Immune Response of Controlled IL-12 Platform in Breast Cancer and Glioblastoma at American Society of Clinical Oncology (ASCO) Annual Meeting

    -Ad-RTS-hIL-12 plus veledimex recruits T cells into breast and brain cancers- Median overall survival reaches 12.7 months in patients with recurrent glioblastoma in 20 mg veledimex cohort who received ...

  • PR Newswire20 days ago

    Isolation and Recombinant Expression of Key Enzyme for Opioid Production

    Long Postulated Enzyme Thebaine Synthase Potentiates Efficient Biosynthesis of Opioids by Increasing Thebaine Titers 20-fold in Engineered Yeast Strains BUDAPEST, Hungary , May 29, 2018 /PRNewswire/ ...

  • PR Newswire25 days ago

    Oxitec Launches Field Trial in Brazil for Next Generation Addition to Friendly™ Mosquitoes Platform

    Oxitec Ltd, a wholly owned subsidiary of Intrexon Corporation (XON), announced that the newest addition to its Friendly™ Aedes aegypti mosquito line, "OX5034", will initiate open field trials on May 23, 2018. OX5034 is the next generation of Oxitec's non-biting Friendly™ Aedes mosquitoes, designed to reduce populations of the disease-spreading Aedes aegypti mosquito. This first field trial of this second generation Friendly™ Aedes mosquito will take place in Indaiatuba, a municipality in the state of São Paulo and part of the metropolitan region of Campinas, Brazil.

  • PR Newswire26 days ago

    The Cayman Government and Oxitec Launch Innovative Pilot to Suppress Aedes aegypti

    The Cayman Islands' Mosquito Research and Control Unit (MRCU) and Oxitec Ltd. (XON) announced today the launch of a new partnership this year as part of the MRCU's efforts to combat Aedes aegypti mosquitoes in the Cayman Islands. The partnership will focus on implementing a new pilot project that will integrate Oxitec's Friendly™ Aedes aegypti mosquitoes with more traditional methods used in integrated vector management ("IVM") efforts, allowing for the evaluation of a combined approach designed to dramatically suppress this vector of Zika, dengue, yellow fever, and chikungunya.

  • PR Newswire26 days ago

    The Cayman Government and Oxitec Launch Innovative Pilot to Suppress Aedes aegypti

    The Cayman Islands' Mosquito Research and Control Unit (MRCU) and Oxitec Ltd. announced today the launch of a new partnership this year as part of the MRCU's efforts to combat Aedes aegypti mosquitoes in the Cayman Islands. The partnership will focus on implementing a new pilot project that will integrate Oxitec's Friendly™ Aedes aegypti mosquitoes with more traditional methods used in integrated vector management ("IVM") efforts, allowing for the evaluation of a combined approach designed to dramatically suppress this vector of Zika, dengue, yellow fever, and chikungunya.

  • Precigen Announces First Patient Dosed in Phase 1 Clinical Study of INXN-4001
    PR Newswire28 days ago

    Precigen Announces First Patient Dosed in Phase 1 Clinical Study of INXN-4001

    GERMANTOWN, Md., May 21, 2018 /PRNewswire/ -- Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation and a biopharmaceutical company specializing in the development of innovative gene and cellular therapies to improve the lives of patients, today announced the treatment of the first patient in a Phase 1 first-in-human clinical trial of its investigational therapy, INXN-4001. "This start of dosing is an exciting and important milestone for Precigen as INXN-4001 is the first investigational new drug (IND) application filed and the first patient dosed for Precigen as a newly formed wholly-owned subsidiary of Intrexon," said Helen Sabzevari, PhD, president of Precigen.

  • GlobeNewswirelast month

    Ziopharm Oncology to Present Data from Clinical Studies of Controlled IL-12 in Breast Cancer and Glioblastoma at American Society of Clinical Oncology (ASCO) Annual Meeting

    -Data from biopsies shows Ad-RTS-hIL-12 plus veledimex recruits killer T cells into breast and brain cancers. -IL-12 continues to demonstrate activity as a single-agent therapy, prolongs survival in patients ...

  • GlobeNewswirelast month

    Recent Analysis Shows H&R Block, Opko Health, Geron, Cardinal Health, Corning, and Intrexon Market Influences — Renewed Outlook, Key Drivers of Growth

    NEW YORK, May 16, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of H&R ...

  • PR Newswirelast month

    Intrexon to Participate in the Bank of America Merrill Lynch 2018 Healthcare Conference

    GERMANTOWN, Md. , May 14, 2018 /PRNewswire/ --  Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today ...

  • ACCESSWIRElast month

    Today’s Research Reports on Stocks to Watch: Intrexon and Supernus Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / May 14, 2018 / While one biotech company went up, the other went down on Friday. Intrexon shares tanked on Friday over first quarter results that didn’t impress traders, as shares of Supernus Pharmaceuticals were galloping ahead on a strong first quarter report. Intrexon Corporation shares closed down almost 20% on Friday with a little over 5 million shares traded.

  • ACCESSWIRElast month

    Free Breakfast Technical Briefing on Intrexon and Three Other Biotech Stocks

    Under assessment are the following four stocks: Intrexon Corp. (NYSE: XON), Iovance Biotherapeutics Inc. (NASDAQ: IOVA), Jaguar Health Inc. (NASDAQ: JAGX), and Jazz Pharmaceuticals PLC (NASDAQ: JAZZ). Germantown, Maryland-based Intrexon Corp.'s stock plummeted 19.64%, finishing last Friday's trading session at $14.98.

  • ACCESSWIRElast month

    Today's Research Reports on Trending Tickers: Intrexon Corporation and Synergy Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / May 11, 2018 / U.S. markets eked out gains on Thursday, on the back of positive economic data and strong performance from the technology sector. The technology sector has gained ...

  • PR Newswirelast month

    Intrexon Announces First Quarter 2018 Financial Results

    - Quarterly GAAP revenues of $43.8 million and net loss attributable to Intrexon of $42.0 million including non-cash charges of $26.3 million - - Adjusted EBITDA of $(19.7) million - GERMANTOWN, Md. , ...

  • GlobeNewswirelast month

    Ziopharm Oncology Reports First Quarter 2018 Financial Results and Provides Corporate Update

    BOSTON, May 10, 2018 (GLOBE NEWSWIRE) --  Ziopharm Oncology, Inc. (ZIOP), today announced financial results for the first quarter ended March 31, 2018, and provided an update on the Company’s recent activities. “The landscapes of CAR-T therapies and the use of cytokines are playing out as anticipated,” said Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm. Dr. Cooper continued, “Immune-stimulatory cytokines have gained significant momentum as potential combination therapies with immune checkpoint inhibitors.

  • GlobeNewswirelast month

    AquaBounty Technologies, Inc. Results for the quarter ended March 31, 2018

    MAYNARD, Mass., May 08, 2018-- AquaBounty Technologies, Inc., a biotechnology company focused on enhancing productivity in the aquaculture market and a majority-owned subsidiary of Intrexon Corporation, ...

  • PR Newswire2 months ago

    Intrexon to Announce First Quarter 2018 Financial Results on May 10th

    GERMANTOWN, Md. , May 3, 2018 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today ...

  • GlobeNewswire2 months ago

    Ziopharm Oncology to Announce First Quarter 2018 Financial Results, Host Conference Call May 10

    The webcast will be recorded and available for replay on the Company's website for two weeks. Ziopharm Oncology is a Boston-based biotechnology company focused on the development of next-generation immunotherapies utilizing gene- and cell-based therapies to treat patients with cancer. In partnership with Precigen Inc., a wholly-owned subsidiary of Intrexon Corporation (XON), Ziopharm is focused on the development of two platform technologies designed to deliver safe, effective and scalable cell- and viral-based therapies for the treatment of multiple cancer types: Controlled IL-12 and Sleeping Beauty for genetically modifying T cells.

  • GlobeNewswire2 months ago

    AquaBounty Technologies, Inc. Announces FDA Approval of First U.S. Facility for Commercial Production of AquAdvantage Salmon

    AquaBounty Technologies, Inc. (AQB) (“AquaBounty” or the “Company”), a biotechnology company focused on enhancing productivity in the aquaculture market and a majority-owned subsidiary of Intrexon Corporation (XON), today announces that it has received approval from the U.S. Food and Drug Administration (FDA) to raise AquAdvantage® Salmon at its land-based contained facility near Albany, Indiana. The FDA previously approved AquaBounty’s New Animal Drug Application (NADA) on November 19, 2015, for the production, sale, and consumption of AquAdvantage Salmon in the United States.

  • PR Newswire2 months ago

    Exemplar Genetics Rare Neurological Disease Model Cleared by FDA for Commercial Research Use

    SIOUX CENTER, Iowa, April 16, 2018 /PRNewswire/ -- Exemplar Genetics, a wholly owned subsidiary of Intrexon Corporation (XON) committed to enabling the study of life-threatening human diseases, today announced the U.S. Food & Drug Administration (FDA) has exercised enforcement discretion in regard to the ExeGen®ATM MiniSwine model clearing it for commercial use as a research model. The ExeGen®ATM MiniSwine is genetically engineered (GE) to model ataxia telangiectasia (AT), a rare, inherited, predominantly neurological human disease.  Exemplar has previously received approval for its ExeGen®LDLR MiniSwine model for use in cardiovascular disease research.

  • ACCESSWIRE2 months ago

    Today’s Research Reports on Trending Tickers: Intrexon and Portola Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / April 3, 2018 / U.S. equities fell sharply on Monday, weighed down by losses in the technology sector and global trade concerns. The Dow Jones Industrial Average decreased 1.90 ...

  • PR Newswire3 months ago

    ActoBio Therapeutics Greenlighted by FDA to Commence a Phase Ib/IIa Trial with AG019 for the Treatment of Early Onset Type 1 Diabetes

    GHENT, Belgium, March 29, 2018 /PRNewswire/ -- ActoBio Therapeutics, a wholly owned subsidiary of Intrexon Corporation (XON) and innovative biotechnology company focused on a new class of orally delivered biopharmaceuticals, and Intrexon T1D Partners LLC, have been granted allowance by the U.S. Food and Drug Administration (FDA) for their Investigational New Drug (IND) application to initiate a Phase Ib/IIa study for the treatment of early onset type 1 diabetes (T1D) with AG019, an innovative disease-modifying approach to induce immune tolerance in T1D.  Currently no disease-modifying treatment for T1D is available, and standard of care is primarily based on exogenous insulin and diet regulation in combination with lifestyle modification.

  • Business Wire3 months ago

    Newman Ferrara LLP Announces Corporate Governance Investigation of Intrexon Corporation - XON

    Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Intrexon Corporation focusing on potential breaches of fiduciary duty by the Company’s Board of Directors .

  • ACCESSWIRE3 months ago

    Today’s Research Reports on Trending Tickers: Intrexon and Opko Health

    NEW YORK, NY / ACCESSWIRE / March 12, 2018 / U.S. markets hiked higher on Friday, with the Dow Jones breaking above the 25,000 threshold, on the back of a stronger-than-expected jobs report. The Dow Jones ...

  • ACCESSWIRE3 months ago

    Today’s Research Reports on Trending Tickers: QEP Resources and Exxon Mobil

    NEW YORK, NY / ACCESSWIRE / March 12, 2018 / U.S. markets hiked higher on Friday, with the Dow Jones breaking above the 25,000 threshold, on the back of a stronger-than-expected jobs report. The Dow Jones ...